These results align with our previous findings in neuroblastoma cell lines, in which ETO treatment dramatically reduced PHOX2B protein levels, while PHOX2B mRNA levels were still reduced, but less affected [39]. The gene discussed is RUNX1T1; the disease is neuroblastoma.